How Incarceration Raises Risk of Cancer Diagnosis and Death—Even After Release
The United States has one of the highest incarceration rates in the world, with nearly 2 million people in the criminal justice system facing potential barriers to accessing timely, quality care. Now, Yale researchers are finding that individuals with a history of incarceration are more likely to be diagnosed with cancer and are less likely to survive the disease.
It's Time to Trade the Moonshot Mentality for a New National Cancer Plan
The fixation on finding a cure for cancer — a moonshot — is diverting our attention, energy and resources from the broader picture. At the 50th anniversary of the National Cancer Act, people are still getting cancers that should be preventable. And profound inequities in cancer burden persist across racial and ethnic groups and social classes. We need a new National Cancer Plan.Source: The Hill
Amy J. Davidoff, PhD, on Racial Disparities in Time to Cancer Treatment: The Effect of Medicaid Expansion
Amy J. Davidoff, PhD, of Yale University School of Public Health, discusses study findings on how expanding access to Medicaid through the Affordable Care Act (ACA) reduced racial disparities among patients with advanced cancer.Source: The ASCO Post
ACA linked to reduced racial disparities, earlier diagnosis and treatment in cancer care
Proponents of the embattled Affordable Care Act got additional ammunition Sunday: New research links the law to a reduction in racial disparities in the care of cancer patients and to earlier diagnoses and treatment of ovarian cancer, one of the most dangerous malignancies.Source: The Washington Post
New Research Points to Obamacare Success in Improving Cancer Treatment as Trump Administration Pushes for Repeal
Two new research studies have shown that the Affordable Care Act—the 2010 legislation commonly referred to as "Obamacare"—had successfully curbed disparities in cancer treatment and allowed many to receive treatment at an earlier stage, while the administration of President Donald Trump has continued to fight to repeal the healthcare legislation.Source: Newsweek
National Cancer Center Partnership Expected to Advance Cancer Research at YSPH, Yale
A new partnership with the National Cancer Center of China will provide opportunities for collaborative research, clinical trials and workforce training at the Yale School of Public Health, Yale Cancer Center and Yale Institute for Global Health.
Yale Cancer Center investigators show recommended, but underused treatment for rare blood cancer saves lives
U.S. and European guidelines on treating Polycythemia Vera (PV), a potentially deadly blood cancer, call for two treatments for patients with high-risk disease: therapeutic phlebotomy and cytoreductive therapy with a drug called hydroxyurea (HU). HU is the most commonly used option, but evidence for HU treatment is limited and both treatments are underused. Now, researchers at Yale Cancer Center (YCC) have documented reduced risk of death and incidence of blood clots in patients receiving those therapies.
Broad genetic testing for advanced lung cancer may not improve survival
Testing for dozens of genetic mutations in tumors of patients with a common form of advanced lung cancer did not appear to improve survival compared to routine genetic testing, a study led by Yale Cancer Center (YCC) scientists has found.
Doctors asking how much post-surgical follow-up is needed
On Saturday, Reisman, 52, a former New York lawyer who now freelances for the Shoreline Times, held a party to celebrate two decades of survival. Looking back on the years after her surgery, Reisman said the fear that the cancer could return was compounded by the anxiety she felt about the multiple MRIs she was required to undergo to make sure it hadn’t. Reisman’s experience has buttressed the concern of Dr. Cary Gross, her brother-in-law, a professor of medicine and epidemiology at the Yale School of Medicine. With new studies showing that multiple surveillance procedures don’t necessarily improve patient outcomes in at least some cancers, he is concerned about whether aggressive post-treatment testing is really necessary, given the anxiety, cost and even occasional false positive results that accompany it.Source: New Haven Register
New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said. However, patients receiving the therapies are older than those in the clinical trials used to evaluate them, pointing to a disconnect between research and practice that should be addressed, they noted.
Disparities found in lung cancer care, survival in U.S. versus England
Despite steady declines in death rates in recent years, lung cancer remains the leading cause of cancer deaths in wealthy countries. In a new study, Yale researchers collaborated with investigators in Europe to examine lung cancer care and survival rates for patients with one of the most common forms of the disease.